65,437 trials
Acellular Pertussis · Poliomyelitis · Tetanus
Primary: Number of Subjects With a Booster Response to Diphtheria (D) and Tetanus (T) Antigens — 176; 90; 173; 90 Participants
Herpes Zoster · Herpes Zoster Vaccine
Primary: Number of Subjects With a Vaccine Response for Anti-gE Antibodies — 394 Participants
Liver Cirrhosis · Hepatic Cirrhosis
Primary: Change From Baseline at Month 3 in cCK18/M30 — 293.5; 257.5; 288.5; 285.0 U/L
Stroke
Primary: Wolf Motor Function Test Change — 1.6; 1.8 seconds
Poliomyelitis · Diphtheria · Tetanus
Primary: Number of Subjects With Any Grade 3 Solicited Local Symptoms — 14; 3; 14; 5 Participants
Low Back Pain
Primary: Roland Morris Low Back Pain Disability Questionnaire (RMDQ) — 4.0; 3.8; 1.0 units on a scale
Sarcoma
Primary: Incidence of Adverse Events Measured by the National Cancer Institute Common Terminology Criteria for Adverse Events Version (v)4.03 — 1; 1; 1; 1 participants
Urinary Urge Incontinence
Primary: Change in Maximum Capacity at Cystoscopy Between Baseline and 6 Month Follow-up — -97.5; 64.1 mL — p=.016
Pelvic Organ Prolapse
Primary: Prolapse by "Pelvic Organ Prolapse Quantification System" (POP-Q), at 12 Months — 8; 38; 75; 46 participants — p=<0.05
Asthma
Primary: Change From Baseline in the Percentage of Total White Blood Cell That Were Eosinophils at 48 Hours — 82.11 percent of white blood cells
Bronchial Asthma
Primary: Forced Expiratory Volume in 1 Second (FEV1) — 2.31; 2.25 liters
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Regimen-Related Toxicities — 21; 10; 8; 16 Toxicities
Osteoarthritis Knee
Primary: Change From Baseline in Visual Analogue Scores (VAS) Following 50-foot Walk Test Through Week 26 — -31.7; -31.7 mm — p=0.988
Graft-Versus-Host-Disease
Primary: Regulatory T Cells (Tregs)/Total CD4+ Cells at Day 30 Post-HCT — 23.8 percentage of CD4+Tregs
Atelectasis
Primary: Change in the Chest X-ray Atelectasis Score — -1; -0.86; -2.18 units on a scale